The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome

被引：6

作者：

Klibanski, Anne ^{[1
]}

Melmed, Shlomo ^{[2
]}

Clemmons, David R. ^{[3
]}

Colao, Annamaria ^{[4
]}

Cunningham, Regina S. ^{[5
]}

Molitch, Mark E. ^{[6
]}

Vinik, Aaron I. ^{[7
]}

Adelman, Daphne T. ^{[6
]}

Liebert, Karen J. P. ^{[8
]}

机构：

[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA

[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA

[3] Univ N Carolina, Sch Med, Chapel Hill, NC 27599 USA

[4] Univ Naples Federico II, Dept Mol & Clin Endocrinol & Oncol, I-80131 Naples, Italy

[5] Robert Wood Johnson Med Ctr, Canc Inst New Jersey, New Brunswick, NJ 08903 USA

[6] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA

[7] Eastern Virginia Med Sch, Dept Internal Med, Norfolk, VA 23510 USA

[8] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA

来源：

PITUITARY | 2010年 / 13卷 / 03期

关键词：

Acromegaly; Carcinoid syndrome; Neuroendocrine tumor; NET; Somatostatin analogs; Somatostatin analogues; Lanreotide; Octreotide; Insulin-like growth factor-I; IGF-I; Growth hormone; GH; GROWTH-FACTOR-I; QUALITY-OF-LIFE; PREOPERATIVE OCTREOTIDE TREATMENT; SECRETING PITUITARY-ADENOMAS; SOMATOSTATIN ANALOG THERAPY; PRIMARY MEDICAL THERAPY; GLUCOSE-TOLERANCE TEST; LONG-ACTING RELEASE; FOLLOW-UP; NEUROENDOCRINE TUMORS;

D O I：

10.1007/s11102-009-0210-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The Endocrine Tumor Summit convened in December 2008 to address 6 statements prepared by panel members that reflect important questions in the treatment of acromegaly and carcinoid syndrome. Data pertinent to each of the statements were identified through review of pertinent literature by one of the 9-member panel, enabling a critical evaluation of the statements and the evidence supporting or refuting them. Three statements addressed the validity of serum growth hormone (GH) and insulin-like growth factor-I (IGF-I) concentrations as indicators or predictors of disease in acromegaly. Statements regarding the effects of preoperative somatostatin analog use on pituitary surgical outcomes, their effects on hormone and symptom control in carcinoid syndrome, and the efficacy of extended dosing intervals were reviewed. Panel opinions, based on the level of available scientific evidence, were polled. Finally, their views were compared with those of surveyed community-based endocrinologists and neurosurgeons.

引用

页码：266 / 286

页数：21

共 2 条

[1] The endocrine tumor summit 2008: appraising therapeutic approaches for acromegaly and carcinoid syndrome
Anne Klibanski
Shlomo Melmed
David R. Clemmons
Annamaria Colao
Regina S. Cunningham
Mark E. Molitch
Aaron I. Vinik
Daphne T. Adelman
Karen J. P. Liebert
Pituitary, 2010, 13 : 266 - 286
[2] Carcinoid syndrome-Symptoms and therapeutic approaches
Chrisoulidou, Alexandra
HELLENIC JOURNAL OF NUCLEAR MEDICINE, 2023, 26 : 52 - 56

← 1 →